This press release is not intended for US or UK media. Ingelheim, Germany and Ridgefield, Conn. Boehringer Ingelheim today announced that The New England Journal of Medicine (NEJM) published results ...
A 1000 mg ×2 induction regimen followed by maintenance every 6–12 months was associated with near-elimination of relapse ...
Biologic-naïve status and higher inflammation predict rapid skin clearance with psoriasis biologics, while palmoplantar ...
A combination of Verzenio and letrozole has shown encouraging and lasting responses in patients with advanced or recurrent ...
March 8, 2011 (Boston, Massachusetts) — Raltegravir (Isentress, Merck) is the antiretroviral drug of choice for treatment-naïve HIV-infected patients. Results from the QDMRK trial indicate that ...
Treatment-naive patients show greater BMD gains taking romosozumab than do patients who had previous antiresorptive treatments. "We conclude that prior antiresorptive therapy, particularly the ...
The PD-1 inhibitor sasanlimab showed anti-tumor activity and manageable safety in combination with BCG induction and maintenance compared with standard of care in patients with BCG-naïve high-risk ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results